We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human||Mouse (Murine)||Rat (Rattus)|
|Western Blotting (WB)||172 Antibodies||84 Antibodies||26 Antibodies|
|Radioimmunoassay (RIA)||1 Antibodies|
|Neutralization (Neut)||30 Antibodies||8 Antibodies||1 Antibodies|
|Mass Cytometry (CyTOF)||1 Antibodies|
|Luminex Assay (LMNX)||2 Antibodies|
|Intracellular Staining (ICS)||11 Antibodies||9 Antibodies||13 Antibodies|
|Intracellular Flow Cytometry (ICFC)||2 Antibodies||2 Antibodies|
|Immunoprecipitation (IP)||5 Antibodies||4 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||14 Antibodies||8 Antibodies||4 Antibodies|
|Immunohistochemistry (IHC)||12 Antibodies|
|Antigen||Interleukin 17A (IL17A) Antibodies|
|Reactivity||Human, Mouse (Murine), Rat (Rattus) Alternatives|
|Conjugate||This IL17A antibody is un-conjugated Alternatives|
Immunohistochemistry (Frozen Sections) (IHC (fro)), Western Blotting (WB)
|4 references available|
|Supplier||Log in to see|
Product Details anti-IL17A AntibodyTarget Details IL17A Application Details Handling References for anti-IL17A Antibody (ABIN493065) Images
|Sequence||NSV PIQ QEI LVL RE PPH C|
|Specificity||This antibody detects a single 18 kDa of IL17. It does not cross reacts with other members of the pro-inflammtory cytokines or with other leukotrienes tested and also does not label any other cellular protein on western blots.|
|Cross-Reactivity (Details)||Species reactivity (tested):Human, mouse, rat|
|Immunogen||Synthetic peptide selective for IL17 from near extra-cytoplasmic domain peptide sequence from N-terminal|
Target Details IL17AProduct Details anti-IL17A Antibody Application Details Handling References for anti-IL17A Antibody (ABIN493065) Images back to top
|Alternative Name||Interleukin-17A (IL17A) (IL17A Antibody Abstract)|
|Background||The primary function of the body defense mechanism/immune system is to protect the organism from invading pathogens. In this regard a very effective and dynamic cellular network has evolved that comprise of innate and adaptive immunity. Most components of innate immunity are present before the onset of infection and constitute cellular and molecular components that recognize classes of molecules peculiar to pathogens. In contrast, adaptive immunity responds to the challenge with a high degree of specificity as well as the remarkable property of memory. Although adaptive immune responses are the most effective to clear invading pathogens (1, 2), innate immune responses should be precedent of activation of adaptive immune cells (2). In other words, adaptive immune responses can not arise without help of innate immune responses. Antigen presenting cells (APCs) are key initiators of immune responses. During infection various cytochines are released and via activation of various TLR receptor family, they synthesized various interleukins. IL17 gene was mapped at a single site on mouse chromosome 1A and human chromosome 2q31 (2). Pro inflammatory cytokine, IL-17 (IL-17A or CTLA-8) plays a central role in inflammation and autoimmunity. The iIL17, like other cytokines is produce by activation of T cell receptor through CD3 cross linking (1). IL-17 is a crucial effector cytokine, whose production is specifically triggered by IL-23, and it has been shown to be an essential inflammatory mediator in other autoimmune diseases and inflammatory conditions. In human the co-stimulation of T cells thru CD28 several costimulatory molecules (ICOS, 4-1BB, CD40L) mildly enhance the IL17 expression where as IL23 profoundly enhance the CD3 induced IL17 expression. The IL-17 expression is also sensitive to cyclosporin-A and MAPK inhibitors, suggesting the involvement of the calcineurin/NFAT and MAPK signaling pathways. The predicted 155-amino acids sequence contains an N-terminal signal peptide and exhibits 72 % amino acid identity with HVS13, an open reading frame from a T-lymphotropic Herpesvirus saimiri, and 63 % with murine CTLA8 (3). Based on hydropathy plot has 2 transmembrane domains (TMD) at N and C-terminal end of the protein.Synonyms: CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17|
|Research Area||Cytokines, Receptors, Inflammation, Immunology, Virology, Cancer|
Application DetailsProduct Details anti-IL17A Antibody Target Details IL17A Handling References for anti-IL17A Antibody (ABIN493065) Images back to top
Immunohistochemistry on frozen sections: 1: 200. Western blot > 1: 500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-IL17A Antibody Target Details IL17A Application Details References for anti-IL17A Antibody (ABIN493065) Images back to top
|Concentration||0.65 - 0.95 mg/mL|
|Buffer||Stabilization buffer with 0.02 % sodium azide as preservative|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Handling Advice||Avoid repeated freezing and thawing.|
|Storage Comment||Store (in aliquots) at -20 °C.|
References for anti-IL17A Antibody (ABIN493065)Product Details anti-IL17A Antibody Target Details IL17A Application Details Handling Images back to top
Huang, Lu, Li et al.: "Occurrence of cGMP/nitric oxide-sensitive store-operated calcium entry in fibroblasts and its effect on matrix metalloproteinase secretion." in: World journal of gastroenterology : WJG, Vol. 12, Issue 34, pp. 5483-9, 2006 (PubMed).
Fossiez, Djossou, Chomarat et al.: "T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines." in: The Journal of experimental medicine, Vol. 183, Issue 6, pp. 2593-603, 1996 (PubMed).
Rouvier, Luciani, Mattéi et al.: "CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 150, Issue 12, pp. 5445-56, 1993 (PubMed).
Yao, Painter, Fanslow et al.: "Human IL-17: a novel cytokine derived from T cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 155, Issue 12, pp. 5483-6, 1996 (PubMed).